INDV1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
SUBLOCADE Growth And ProtectionSUBLOCADE's 21% Q2 sales growth, record new patient starts and roughly 76% market share indicate sustained commercial traction. Its long-acting format, low current LAI penetration and patent coverage through 2031–2038 support a multi-quarter growth runway.
Merger Scale And SynergiesThe Supernus combination would broaden Indivior into 11 marketed medicines and approximately $2.2B of pro forma revenue. Portfolio expansion and the $125M annual cost-synergy target could improve scale, operating leverage and capacity for future growth.
Profitability ReboundTTM profitability has rebounded, with healthy gross and net margins after losses in 2022–2023 and weak 2024 results. The improvement suggests better operating leverage and provides a stronger earnings base for investment in marketed growth products.
Bears Say
Weak Cash ConversionNegative TTM operating and free cash flow, also seen in 2025, shows that reported earnings are not consistently converting into cash. Volatile cash conversion can limit internally funded investment and increase reliance on balance-sheet flexibility during product investment or transaction execution.
Persistently Negative EquityPersistently negative shareholders’ equity, despite sharply lower TTM debt, leaves the capital structure less resilient. An equity deficit can amplify downside in a weaker operating period and reduce flexibility to absorb setbacks while the company funds growth and completes its planned combination.
SUBLOCADE ConcentrationSUBLOCADE is expected to contribute about 44% of pro forma revenue, so a slowdown in adoption, payer access or competitive dynamics could have an outsized effect. The merger increases scale but does not eliminate dependence on one principal growth engine.
Indivior News
INDV1 FAQ
What was Indivior PLC’s price range in the past 12 months?
Currently, no data Available
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is $69.07B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Oct 29, 2026 which is in 46 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Aug 03, 2026. The company reported $19.589 earnings per share for the quarter, beating the consensus estimate of $14.803 by $4.787.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 17.99.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 118,013,650 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $19.589 in its last earnings report, beating expectations of $14.803. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in MX:INDV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$814.57 (― Upside)
$814.57 (― Upside)
Blogger Sentiment
Bullish
MX:INDV1 Sentiment 83%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
INDV1 Company Deck
INDV1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presents a constructive and optimistic view of the merger: management emphasized scale, a diversified portfolio (~$2.2B pro forma revenue), strong pro forma profitability (adjusted EBITDA $888M; ~41% margin), and $125M of near-term cost synergies, while retaining balance sheet strength and highlighting SUBLOCADE as a durable, large growth driver (~44% of revenue) supported by IP and commercial momentum. Noted risks include revenue concentration in SUBLOCADE, increased pro forma net debt (~$878M, ~1x leverage), absence of quantified revenue synergies, and standard integration and regulatory execution risks. On balance, the positives (scale, margins, synergies, product durability) outweigh the lowlights.View all MX:INDV1 earnings summaries